The theoretical 25-35% total body weight reduction potential makes this stack particularly relevant for individuals with a higher starting weight who need more than what single-agent therapy can deliver
doi: 10.7554/eLife.21690 157 BrosiusFCCowardRJ
SLIMMER Phase 3 (ecnoglutide, 40 weeks): Key characteristics: Lowest discontinuation rate among the drugs compared here (~2%) GI events described as "mild-to-moderate" with no detailed breakdown of individual symptom rates publicly available The biased agonism profile may contribute to reduced severity of GI effects Discontinuation rates of 6-11% across dose groups (including all causes, not just AEs) Demonstrates that cAMP bias may translate to a clinically meaningful tolerability advantage CT-388# CT-388 is a signal-biased dual GLP-1/GIP receptor agonist developed by Roche/Genentech
Tap out any air bubbles and adjust to the exact number of units you need
Coates has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB